Study of the Safety, Tolerability, Pharmacokinetics of VV261 Tablets in Chinese Healthy Volunteers
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of a Single Oral Dose of VV261 Tablets in Chinese Healthy Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Huaqing Duan
- Phone Number: 18061926005
- Email: huaqing.duan@vigonvita.cn
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230031
- Recruiting
- The First Affiliated Hospital of Anhui Medical University
-
Contact:
- Huan Zhou
-
Principal Investigator:
- Huan Zhou
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 18 to 45 years old, males or females;
- Males weight no less than 50 kg, females weight no less than 45 kg, with body mass index of 19 to 26 kg/m^2;
- Vital signs examination, physical examination, laboratory examination ,electrocardiogram examination chest CT and B-ultrasound of liver, gallbladder, pancreas, spleen, kidney and thyroid results are normal or considered abnormal without clinical significance by the investigator;
- Volunteers who are willing to take proper contraceptive methods during the study and within 3 months after the the last administration;
- Volunteers who are able to understand and follow the study protocol and instructions; volunteers who have voluntarily decided to participate in this study, and sign the informed consent form.
Exclusion Criteria:
- Volunteers with hypersensitivity to preparation or any of the excipients;
- Volunteers with allergic constitution (such as asthma, urticaria, eczematous dermatitis and other allergic diseases), or have a history of drug or food allergy;
- Volunteers with central nervous system, cardiovascular system, gastrointestinal, respiratory system, urinary, hematologic, or metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials;Volunteers with a history of gastrointestinal conditions that may impair drug absorption (e.g., gastrectomy or small intestine resection, atrophic gastritis, gastrointestinal ulcers or perforations/fistulas, gastrointestinal bleeding, or obstruction);
- Volunteers with a history of diseases affecting bone marrow hematopoietic function or reducing immunological function (including leukemia, myelodysplastic syndrome, aplastic anemia, systemic lupus erythematosus, rheumatoid arthritis, etc.) or treatment history (tumor chemotherapy or radiotherapy, use of immunosuppressants, etc.);
- Volunteers with a history of spleen diseases;
- If any of the following parameters were considered abnormal with clinical significance: white blood cell count, red blood cell count, platelet count, reticulocyte count, and absolute neutrophil count;
- If any of the following parameters were considered abnormal with clinical significance: total bilirubin, alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase;
- Volunteers who have received blood transfusion or used blood products within 3 months before screening or who have lost more than ≥400 mL of blood due to other reasons (excluding menstruation);
- Volunteers who have participated in clinical trials and received drugs within 3 months before screening;
- Volunteers who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 2 weeks before screening;
- Volunteers who have received vaccination within the first 2 weeks before screening, or planned to receive any vaccine during the trial or within 1 week after the end of the study;
- Volunteers with a history of drug abuse within 1 year before screening or positive urine drug screening within 1 year before screening results (morphine, tetrahydrocannabinol, methamphetamine, dimethylene diphenazine , ketamine, and cocaine);
- Volunteers who drink more than 14 standard units or at least twice a day per week within one year before screening,(one standard unit equals 200 mL of beer with 5% alcohol or 25 mL of white wine with 40% alcohol content or 85 mL of red wine with 12% alcohol);
- Volunteers who smok more than 5 cigarettes a day within one year before screening;
- Volunteers who can't quit smoking or drinking during the trial period;
- Volunteers who are positive for hepatitis B virus surface antigen, hepatitis C virus antibody, treponema pallidum antibody or human immunodeficiency virus antibody (Anti-HIV);
- Volunteers who cannot tolerate blood collection with intravenous indwelling needles or blood fainting;
- Volunteers with lactose intolerance or cannot comply with a uniform diet (such as special dietary requirements, intolerance of standard meals, etc.), volunteers who have consumed excessive amounts of strong tea, coffee or caffeinated beverages in the 3 months before screening;
- Volunteers with difficulty in swallowing tablets;
- Pregnant or lactating women or male volunteers whose female partners plan to conceive within 3 months;
- The investigator believes that there are other unsuitable factors to participate this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
6 subjects receive VV261 20mg,orally; 2 subjects will receive placebo,orally.
6 subjects receive VV261 50mg,orally; 2 subjects will receive placebo,orally.
6 subjects receive VV261 100mg,orally; 2 subjects will receive placebo,orally.
6 subjects receive VV261 150mg,orally; 2 subjects will receive placebo,orally.
6 subjects receive VV261 300mg,orally; 2 subjects will receive placebo,orally.
6 subjects receive VV261 500mg,orally; 2 subjects will receive placebo,orally.
6 subjects receive VV261 750mg,orally; 2 subjects will receive placebo,orally.
6 subjects receive VV261 1000mg,orally; 2 subjects will receive placebo,orally.
|
|
Experimental: VV261
|
2 subjects will receive VV261 5mg, orally
6 subjects receive VV261 20mg,orally; 2 subjects will receive placebo,orally.
6 subjects receive VV261 50mg,orally; 2 subjects will receive placebo,orally.
6 subjects receive VV261 100mg,orally; 2 subjects will receive placebo,orally.
6 subjects receive VV261 150mg,orally; 2 subjects will receive placebo,orally.
6 subjects receive VV261 300mg,orally; 2 subjects will receive placebo,orally.
6 subjects receive VV261 500mg,orally; 2 subjects will receive placebo,orally.
6 subjects receive VV261 750mg,orally; 2 subjects will receive placebo,orally.
6 subjects receive VV261 1000mg,orally; 2 subjects will receive placebo,orally.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AUC0-t
Time Frame: 48 hours after administration
|
area under the plasma concentration time curve from time zero to the last measurable concentration
|
48 hours after administration
|
|
Tmax
Time Frame: 48 hours after administration
|
time at which Cmax occurs
|
48 hours after administration
|
|
CLz/F
Time Frame: 48 hours after administration
|
apparent clearance
|
48 hours after administration
|
|
t1/2
Time Frame: 48 hours after administration
|
half life of elimination
|
48 hours after administration
|
|
Vd/F
Time Frame: 48 hours after administration
|
apparent volume of distribution during the terminal phase
|
48 hours after administration
|
|
AUC0-∞
Time Frame: 48 hours after administration]
|
area under the plasma concentration-time curve from time zero to infinity
|
48 hours after administration]
|
|
MRT
Time Frame: 48 hours after administration
|
mean residence time
|
48 hours after administration
|
|
Cmax
Time Frame: 48 hours after administration]
|
maximum observed plasma concentration
|
48 hours after administration]
|
|
Kel
Time Frame: 48 hours after administration
|
elimination rate constant
|
48 hours after administration
|
|
AE & SAE
Time Frame: from day1 to day7 after administration
|
Adverse event & serious adverse events
|
from day1 to day7 after administration
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Huan Zhou, The First Affiliated Hospital of Anhui Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- VV261-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.